Supplementary Table S4 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

Autor: Dirk Schadendorf, Levi A. Garraway, Gad Getz, Scott L. Carter, Stacey B. Gabriel, Jessica C. Hassel, Benjamin Weide, Carmen Loquai, Uwe Trefzer, Carola Berking, Friederike Egberts, Helen J. Gogas, Selma Ugurel, Simone M. Goldinger, Ralf Gutzmer, Uwe Hillen, Lisa Zimmer, Deborah Farlow, Kristian Cibulskis, Aaron McKenna, Mara Rosenberg, Eran Hodis, Gregory V. Kryukov, Steven Whittaker, Amaro Taylor-Weiner, Chelsea S. Place, Eva M. Goetz, Cory M. Johannessen, Daniel J. Treacy, Antje Sucker, Nikhil Wagle, Eliezer M. Van Allen

PDF file, 12065K, Supplementary Table S4. Complete listing of all somatic mutations seen in all tumors. This table provides details on every non-synonymous mutation or short insertion/deletion observed in this cohort, with data on genomic coordinates

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5506ae088ed88f5f363d9c3bc77d56e0
https://doi.org/10.1158/2159-8290.22530882.v1

Supplementary material from A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

Autor: Fernando Ulloa-Montoya, Jamila Louahed, Vincent G. Brichard, Bart Spiessens, Channa Debruyne, Patrick Therasse, Fawn Wang, Susana Salceda, Hans van Houwelingen, Jelle Goeman, Djordje Atanackovic, Lecia V. Sequist, Johan F. Vansteenkiste, John M. Kirkwood, Helen J. Gogas, Peter Hersey, Brigitte Dreno, Muriel Debois, Andrea Callegaro, Benjamin Dizier

Supplementary material

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5528f31009db1e47f0a2c403009ea8f6
https://doi.org/10.1158/1078-0432.22473330.v1

Supplementary Tables 1-13 from 19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus

Autor: Fergus J. Couch, Douglas F. Easton, Ylermi Soini, Jaana M. Hartikainen, Veli-Matti Kosma, Arto Mannermaa, Xiaoqing Chen, Jonathan Beesley, Georgia Chenevix-Trench, Marie-Rose Christiaens, Anne-Sophie Dieudonne, Sigrid Hatse, Diether Lambrechts, Monica Barile, Siranoush Manoukian, Paolo Peterlongo, Paolo Radice, Janet E. Olson, Susan Slager, V.S. Pankratz, Matthew L. Kosel, Gianluca Severi, Catriona A. McLean, Laura Baglietto, Graham G. Giles, Anne-Lise Børresen-Dale, Vessela Kristensen, Grethe Grenaker Alnæs, Alexander Miron, Esther M. John, Mervi Grip, Arja Jukkola-Vuorinen, Katri Pylkäs, Robert Winqvist, Anna Marie Mulligan, Gord Glendon, Julia A. Knight, Irene L. Andrulis, Maartje J. Hooning, Rob A.E.M. Tollenaar, Caroline Seynaeve, Peter Devilee, Jolanta Lissowska, Mark E. Sherman, Jonine D. Figueroa, Montserrat Garcia-Closas, Diana M. Eccles, Helena Hwang, Foluso Ademuyiwa, Christine B. Ambrosone, Kamila Czene, Per Hall, Malcom W. Reed, Simon S. Cross, Angela Cox, Qin Wang, Manjeet K. Humphreys, Alison M. Dunning, Paul P. Pharoah, Hans Ulrich Ulmer, Thomas Rüdiger, Thomas Dünnebier, Ute Hamann, Chia-Ni Hsiung, Huan-Ming Hsu, Jyh-Cherng Yu, Chen-Yang Shen, Christina Clarke Dur, Leslie Bernstein, Argyrios Ziogas, Hoda Anton-Culver, Minouk J. Schoemaker, Nicholas Orr, Alan Ashworth, Anthony J. Swerdlow, Melissa C. Southey, Daniel J. Park, Carmel Apicella, John L. Hopper, Efraim H. Rosenberg, Linde M. Braaf, Annegien Broeks, Marjanka K. Schmidt, Surapon Wiangnon, Puttisak Puttawibul, Kenneth Muir, Artitaya Lophatananon, Arif B. Ekici, Arndt Hartmann, Matthias W. Beckmann, Peter A. Fasching, Isabel dos Santos Silva, Olivia Fletcher, Nichola Johnson, Julian Peto, Michael J. Kerin, Ian Tomlinson, Elinor Sawyer, Christof Sohn, Andreas Schneeweiss, Frederick Marmé, Barbara Burwinkel, Emilie Cordina-Duverger, Florence Menegaux, Thérèse Truong, Pascal Guénel, Henrik Flyger, Børge G. Nordestgaard, Sune F. Nielsen, Stig E. Bojesen, José Ignacio Arias Pérez, María Pilar Zamora, Javier Benítez, Roger L. Milne, Annie Perkins, Miriam Dwek, Ruth Swann, Helen J. Gogas, George Fountzilas, Alexandra Stavropoulou, Drakoulis Yannoukakos, Penelope Miron, Christa Stegmaier, Volker Arndt, Heiko Müller, Hermann Brenner, Priyanka Sharma, Harsh B. Pathak, JoEllen Weaver, Andrew K. Godwin, Christoph Engel, Sarah Schott, Claus R. Bartram, Alfons Meindl, Rita K. Schmutzler, Hans-Peter Fischer, Yon-Dschun Ko, Hiltrud Brauch, Stefan Nickels, Shan Wang-Gohrke, Hans-Peter Sinn, Dieter Flesch-Janys, Alina Vrieling, Jenny Chang-Claude, Carl Blomqvist, Kristiina Aittomäki, Dario Greco, Heli Nevanlinna, Annika Lindblom, Sara Margolin, Xianshu Wang, Celine M. Vachon, Zachary Fredericksen, Kristen N. Stevens

PDF file - 272K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739f2fe1c24891c344f70a4e8949d5d0
https://doi.org/10.1158/0008-5472.22393569.v1

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Autor: Hussein A, Tawbi, Dirk, Schadendorf, Evan J, Lipson, Paolo A, Ascierto, Luis, Matamala, Erika, Castillo Gutiérrez, Piotr, Rutkowski, Helen J, Gogas, Christopher D, Lao, Juliana Janoski, De Menezes, Stéphane, Dalle, Ana, Arance, Jean-Jacques, Grob, Shivani, Srivastava, Mena, Abaskharoun, Melissa, Hamilton, Sarah, Keidel, Katy L, Simonsen, Anne Marie, Sobiesk, Bin, Li, F Stephen, Hodi, Georgina V, Long, Sajeve, Thomas

Publikováno v: The New England journal of medicine. 386(1)

BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0feb8c15306160d75f7490cd16650a6e
https://pubmed.ncbi.nlm.nih.gov/35544393

Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Autor: Reinhard Dummer, Nuzhat Pathan, Zhou Zhu, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Michelle Edwards, Jean Cantey-Kiser, Alessandra di Pietro, Shibing Deng, Paolo A. Ascierto, Keith Flaherty

Publikováno v: Cancer Research. 82:6403-6403

Background: In the randomized, two-part, phase 3 COLUMBUS study (NCT01909453), encorafenib (enco) + binimetinib (bini) and enco alone improved 5-year progression-free survival (PFS) and overall survival (OS) vs vemurafenib (vem) in patients (pts) wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e1594f455f58cb479c7df16fc29cf72
https://doi.org/10.1158/1538-7445.am2022-6403